Showing results (1241-1250 of 1,469) with videos related to
Sort By:
Pageof 147
EFSA Journal. European Food Safety Authority|July 7, 2020
Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β-unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19, Maged Younes, Gabriele Aquilina, et al.EFSA Journal. European Food Safety Authority|July 7, 2020
Scientific Opinion on Flavouring Group Evaluation 217 Revision 2 (FGE.217Rev2), consideration of genotoxic potential for α,β-unsaturated ketones and precursors from chemical subgroup 4.1 of FGE.19: lactones, Maged Younes, Gabriele Aquilina, et al.Current Pharmaceutical Design|April 17, 2013
Immune system, cell senescence, aging and longevity--inflamm-aging reappraisedStefano Salvioli, Daniela Monti, Catia Lanzarini, et al.Journal of Neuroimmunology|August 14, 2023
Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumabAlessandra Sottini, Virginia Quaresima, Mosè Barbaro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2018
BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid CancerFei Wang, Shihua Zhao, Xiaopei Shen, et al.Orphanet Journal of Rare Diseases|September 2, 2020
Providing high-quality care remotely to patients with rare bone diseases during COVID-19 pandemicE Brizola, G Adami, G I Baroncelli, et al.The Journal of Clinical Endocrinology and Metabolism|July 17, 2021
BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid CancerYubing Tao, Fei Wang, Xiaopei Shen, et al.Journal of the Neurological Sciences|July 21, 2009
Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatmentM Trojano, F Pellegrini, D Paolicelli, et al.Biomedicines|February 24, 2024
Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life PerspectiveMarco Caminati, Matteo Maule, Roberto Benoni, et al.EFSA Journal. European Food Safety Authority|August 21, 2020
Opinion on the re-evaluation of starch sodium octenyl succinate (E 1450) as a food additive in foods for infants below 16 weeks of age and the follow-up of its re-evaluation as a food additive for uses in foods for all population groups, Maged Younes, Gabriele Aquilina, et al.Pageof 147